Chifuku Ito

Mrs. Chifuku Ito

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2024 in Respiratory Investigation
Verified
Journal Article
Open access
Toru OgaToru Oga
Toru Oga
CIChifuku Ito
Chifuku Ito
RIRisako Ito
Risako Ito
GRGema Requena
Gema Requena
KRKieran J. Rothnie
Kieran J. Rothnie
MYMasao Yarita
Masao Yarita
Real-world data assessing characteristics of patients with asthma initiating inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy in Japan are limited. Descriptive, observational study of patients with asthma aged ≥15 years newly initiating single- or multiple-inhaler triple therapy (SITT: fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI], SITT: indacaterol/glycopyrronium bromide/mometasone furoate [IND/GLY/MF] or MITT) or ICS/LABA using JMDC/Medical Data Vision (MDV) health insurance databases from February 2021-February 2022 (first prescription date: index date). Patients were assigned to three non-mutually exclusive cohorts: A) new FF/UMEC/VI initiators; B) new FF/UMEC/VI, IND/GLY/MF, or MITT initiators; C) new FF/UMEC/VI, IND/GLY/MF, MITT or ICS/LABA initiators as initial maintenance therapy (IMT). Patient characteristics were assessed descriptively for 12-months pre-treatment initiation (baseline period). Cohort A: among new FF/UMEC/VI initiators, 12.8% and 0.1% (JMDC) and 21.7% and 0.9% (MDV) of patients had ≥1 moderate and severe exacerbation; 52.0% (JMDC) and 79.2% (MDV) had ICS/LABA use. Cohort B: most patients initiated FF/UMEC/VI and IND/GLY/MF over MITT (JMDC: 91.3% vs 8.7%; MDV: 67.8% vs 32.2%), with fewer exacerbations and lower rescue medication use. Cohort C: a greater proportion of FF/UMEC/VI initiators as IMT experienced a moderate exacerbation at index versus ICS/LABA initiators as IMT (JMDC: 17.8% vs 10.7%; MDV: 8.0% vs 5.1%). Patient characteristics were generally similar between treatment groups; SITT initiators had fewer exacerbations and lower rescue medication use than MITT initiators, represented by the greater proportion of IMT among SITT versus MITT initiators. Physicians may have prescribed triple over dual therapy as IMT in response to an exacerbation.

5 May 2025 in Respiratory Investigation
Verified
Journal Article
Open access
Toru OgaToru Oga
Toru Oga
RIRisako Ito
Risako Ito
CIChifuku Ito
Chifuku Ito
MTMasashi Takano
Masashi Takano
GRGema Requena
Gema Requena
MYMasao Yarita
Masao Yarita
Real-world evidence of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) use in Japan is limited. This real-world study assessed adherence to FF/UMEC/VI once-daily single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) among patients with asthma in Japan. Retrospective observational cohort study of patients with asthma initiating FF/UMEC/VI SITT or MITT, using claims data (02/18/2021-02/28/2022, JMDC database). Patients were aged ≥15 years at index (date of FF/UMEC/VI or MITT claim). Outcomes were assessed in two cohorts and weighted using inverse probability of treatment weighting: 1) 'overall cohort' included patients who received FF/UMEC/VI or MITT as initial maintenance therapy (IMT) or as non-IMT (i.e., had previously received inhaled corticosteroid-containing medication during baseline); 2) 'non-IMT cohort' was a sub-cohort of the overall cohort. proportion of adherent patients (proportion of days covered ≥0.8) in the 3, 6, and 12 months after, and including, index date. The overall cohort comprised 7228 (FF/UMEC/VI) and 864 (MITT) patients. Of these, 3623 and 735 were included in the FF/UMEC/VI and MITT non-IMT cohort, respectively. At 3 months post-index, a significantly higher proportion of patients were adherent to FF/UMEC/VI (36.4 % [n = 2631]) versus MITT (31.2 % [n = 270]) in the overall cohort (rate ratio [95 % confidence interval], 1.16 [1.05-1.29], p = 0.003, weighted), and FF/UMEC/VI (36.6 % [n = 1326]) versus MITT (28.9 % [n = 213]) in the non-IMT cohort (1.26 [1.12-1.43], p < 0.001). Similar results were observed at 6, and 12 months post-index. Patients with asthma in Japan who initiated FF/UMEC/VI SITT had significantly better treatment adherence than those who initiated MITT.

Verified
Journal Article
Open access
PDF file
Toru OgaToru Oga
Toru Oga
YGYasuhiro Gon
Yasuhiro Gon
MTMasashi Takano
Masashi Takano
RIRisako Ito
Risako Ito
CIChifuku Ito
Chifuku Ito
MYMasao YARITA
Masao YARITA
Background: Japanese guidelines recommend the addition of a long-acting muscarinic antagonist for patients with asthma uncontrolled on inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy, the effectiveness of which is evaluated here. Methods: Retrospective, observational, single-arm cohort study in patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) following ICS/LABA, using independently analyzed data from Japanese claims databases: JMDC and Medical Data Vision (MDV). The index date was that of the first FF/UMEC/VI prescription. Outcomes were assessed during a 12-month follow-up versus a 12-month pre-index period (baseline) and included asthma exacerbations, oral corticosteroid (OCS) use, and short-acting β2-agonist (SABA) use. P-values associated with rate ratios (RRs) were estimated using Conditional Poisson regression. Results: Overall, 3229 patients in the JMDC database and 1135 in the MDV database were included. Following FF/UMEC/VI initiation, the total annualized moderate–severe asthma exacerbation rate in the JMDC database reduced from 0.50 to 0.40 per-person-per-year (PPPY) (RR [95% confidence interval]: 0.78 [0.73, 0.84]; p < 0.001), with similar reductions in the MDV database: 0.53 to 0.42 PPPY (0.79 [0.70, 0.89]; p < 0.001). In both databases, there was a 20% reduction (JMDC: 0.80 [0.73, 0.88]; p < 0.001; MDV: 0.80 [0.68, 0.94]; p = 0.005) in patients with ≥1 OCS prescription after FF/UMEC/VI initiation. The proportion of patients with ≥1 SABA canister prescription dropped by 31% 0.69 [0.57, 0.84]; p < 0.001) in the JMDC database and 23% (0.77 [0.66, 0.90]; p < 0.001) in the MDV database. Conclusions: This suggests FF/UMEC/VI is effective in improving asthma exacerbations and reducing OCS and SABA use in Japanese patients previously using ICS/LABA in real-world clinical practice.